By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intensity Therapeutics, Inc. 

8 Wright Street
Suite 107
Westport  Connecticut  06880  U.S.A.
Phone: 203-682-2434 Fax: 203-664-1051


Intensity Therapeutics is a biotechnology company whose mission is to greatly extend the lives of cancer patients. Late stage solid cancer consists of well-defined visible tumors and unseen micro-metastases either in the blood or body tissue. Cancer is thus both a regional and a systemic disease. To have an effective treatment against cancer one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics was thus founded to develop a new approach to treat both the big and the small aspects of the disease - in situ vaccination. Using our DfuseRxSM platform, we create novel formulations of proven drugs. Our products have high diffusion and dispersion properties in tumors. When injected directly into a tumor or visible metastases these products are able to kill the tumors and create sites for an adaptive immune response. The observed adaptive immune response further increases the efficacy of our system to destroy or regress the tumor, eliminate secondary tumors and micrometastases as well. The Company demonstrated that complete regression (CR) of large tumors in mice is possible using the technology. Animals that had a CR became fully resistant to re-inoculation of the same cancer.




CEO: Lewis H. Bender

Chief Medical Officer: Ian B. Walters, MD

Key Statistics

Ownership: Private

Web Site: Intensity Therapeutics, Inc.

Company News
Intensity Therapeutics, Inc. Issued New Patents For Technology Platform 6/15/2017 6:27:39 AM
Intensity Therapeutics, Inc. Successfully Administers INT230-6 To First Patient In A Phase I/II Trial 5/30/2017 5:47:12 AM
Intensity Therapeutics, Inc. Reports That INT230-6 Induces Protective T-Cell Immunity In Preclinical Models 4/4/2017 7:42:53 AM
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6 6/28/2016 10:46:04 AM
Intensity Therapeutics, Inc. Issued First U.S. Patent For Immune-based Cancer Therapeutic Agents 6/2/2016 11:30:04 AM
Intensity Therapeutics, Inc. Reports That INT230-6’s Anti-Cancer Mechanism Is A Combination Of Cell Death With Immune System Activation 4/19/2016 12:38:12 PM
Intensity Therapeutics, Inc. Selected To Present At BioCentury Future Leaders Conference 3/8/2016 10:21:48 AM
Intensity Therapeutics, Inc. Reports Anti-Cancer Immunological Effect Generated By INT230-6 3/3/2016 1:28:18 PM
Intensity Therapeutics, Inc. Reports Anti-Cancer Immunological Effect Generated By INT230-6 3/3/2016 10:51:23 AM
Intensity Therapeutics, Inc. Preclinical Results Show Anti-Cancer Synergy Of INT230-6 With Anti-PD-1 Compounds 11/5/2015 1:04:32 PM